Success Metrics

Clinical Success Rate
100.0%

Based on 7 completed trials

Completion Rate
100%(7/7)
Active Trials
0(0%)
Results Posted
29%(2 trials)

Phase Distribution

Ph phase_2
3
33%
Ph not_applicable
2
22%
Ph phase_3
3
33%
Ph phase_1
1
11%

Phase Distribution

1

Early Stage

3

Mid Stage

3

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
1(11.1%)
Phase 2Efficacy & side effects
3(33.3%)
Phase 3Large-scale testing
3(33.3%)
N/ANon-phased studies
2(22.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

87.5%

7 of 8 finished

Non-Completion Rate

12.5%

1 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(7)
Terminated(1)
Other(1)

Detailed Status

Completed7
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (11.1%)
Phase 23 (33.3%)
Phase 33 (33.3%)
N/A2 (22.2%)

Trials by Status

completed778%
unknown111%
withdrawn111%

Recent Activity

0 active trials
Showing 5 of 9
completedphase_3

A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis

NCT02950155
completedphase_2

Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL)

NCT02251041
completedphase_3

RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis.

NCT02746744
completednot_applicable

Effect of Intraoperative Lidocaine Infusion on Intraoperative Isoflurane Requirements

NCT03386565
unknownphase_3

Evaluation if Physostigmine Reduces Symptoms in Patients Who Has Developed a Delirium in Intensive Care After a Surgery

NCT02216266
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT02950155Phase 3

A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis

Completed
NCT02251041Phase 2

Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL)

Completed
NCT02746744Phase 3

RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis.

Completed
NCT03386565Not Applicable

Effect of Intraoperative Lidocaine Infusion on Intraoperative Isoflurane Requirements

Completed
NCT02216266Phase 3

Evaluation if Physostigmine Reduces Symptoms in Patients Who Has Developed a Delirium in Intensive Care After a Surgery

Unknown
NCT01503840Not Applicable

Evaluation of Accelerometer-Based Neuromuscular Monitoring Reliability to Exclude Postoperative Residual Paralysis

Completed
NCT01925001Phase 2

Phase 2 Study of MP4CO to Treat Vaso-occlusive Sickle Crisis

Withdrawn
NCT01356485Phase 1

Safety Study of MP4CO in Adult Sickle Cell Patients

Completed
NCT00927836Phase 2

AXIS 2: AX200 for the Treatment of Ischemic Stroke

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9